Abstract:Abstract Oncogenic RAS signaling drives tumor growth in about 30% of human malignancies. In recent years the first mutant-specific inhibitors of KRAS G12C (sotorasib and adagrasib) entered the clinic. While some durable responses were noted in KRAS-mutant non-small cell lung cancer, the clinical experience of KRAS G12C inhibitors is marked by rapid drug resistance, either intrinsic or acquired, causing re-activation of the MAPK pathway. Common resistance mechanisms include compensatory signaling through the related RAS isoforms NRAS and HRAS, as well as the selection of non-G12C KRAS mutations, among others. The bacterial peptidase RRSP potently cleaves all RAS mutants and isoforms in the conserved Switch I region. We have shown that receptor-mediated intracellular delivery of RRSP using an engineered protein delivery system (RASx) can inactivate all RAS signaling in a cell, causing apoptosis in RAS-addicted tumor cells in vitro and in vivo. Since systemic pan-RAS inhibition is not likely to be tolerated therapeutically, precise tumor targeting is a necessary feature of a true pan-RAS inhibitor. Here, we describe the unique ability of the RASx system to specify the cell surface receptor used by RRSP to enter cells, allowing exquisite targeting and killing of KRAS, NRAS and HRAS-driven tumor cells while sparing healthy tissues. We screened a panel of patient-derived tumor organoids (PDOs), to demonstrate broad tumor cell killing across pancreatic and colorectal cancer-derived PDOs. 97% of KRAS mutant organoids were sensitive to RASx, independent of the specific mutation. Intriguingly, 46% of wildtype RAS PDOs were sensitive to RASx, including organoids with activating mutations in EGFR. In contrast, PDOs with mutations downstream of RAS such as BRAF V600E were resistant to RASx. Indeed, RASx is effective not only against RAS-addicted tumors, but also wildtype RAS tumors driven by upstream receptor tyrosine kinases, potentially expanding the clinical utility of this platform. RASx is a first-in-class, tumor-targeted pan-RAS inhibitor that represents a unique entry into the growing armamentarium against oncogenic RAS. Citation Format: Greg L. Beilhartz, Huazhu Liang, Molly Udaskin, Christine Ng, Nikolina Radulovich, Roman A. Melnyk. Pan-RAS inhibition by a tumor-targeted biotherapeutic [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1216.

A CRISPR-Cas13a System for Efficient and Specific Therapeutic Targeting of Mutant KRAS for Pancreatic Cancer Treatment.

Precise and efficient silencing of mutant Kras<SUP>G12D</SUP> by CRISPR-CasRx controls pancreatic cancer progression

Selective Targeting of the Oncogenic KRAS G12S Mutant Allele by CRISPR/Cas9 Induces Efficient Tumor Regression

Selective Targeting of an Oncogenic KRAS Mutant Allele by CRISPR/Cas9 Induces Efficient Tumor Regression

Mutant KRAS is a druggable target for pancreatic cancer

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer

Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer

A CRISPR-Cas9 repressor for epigenetic silencing of KRAS

Genome Editing of Mutant KRAS Through Supramolecular Polymer-Mediated Delivery of Cas9 Ribonucleoprotein for Colorectal Cancer Therapy.

Survival of pancreatic cancer cells lacking KRAS function

A Pancreatic Cancer Organoid Platform Identifies an Inhibitor Specific to Mutant KRAS.

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

A Recombinant Chimeric Protein Specifically Induces Mutant Kras Degradation And Potently Inhibits Pancreatic Tumor Growth

A Pan-Kras Degrader for the Treatment of KRAS-mutant Cancers.

Abstract 1673: KRAS dependency, a gene editing approach

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Disruption of the pro-oncogenic c-RAF–PDE8A complex represents a differentiated approach to treating KRAS–c-RAF dependent PDAC

Abstract 1216: Pan-RAS inhibition by a tumor-targeted biotherapeutic

Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer

Therapeutic expression of RAS Degrader RRSP in Pancreatic Cancer via Nanocarrier-mediated mRNA delivery